Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Neoadjuvant Chemotherapy in High-Risk ER+/HER2- Breast Cancer
NCT06500208Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Nov 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06500208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500208.